The Global Blow Fill Seal CDMO Market Size is predicted to record at a 4.81% CAGR during the forecast period for 2023-2031.
The demand for packaging to treat both communicable and non-communicable diseases is rising due to the global expansion of the pharmaceutical sector. As a result, the packaging is increasingly in demand in the pharmaceutical industry since it shields drugs from injury, biological contamination, and environmental factors. Technological developments in the business and rising pharmaceutical demand contribute to the rising need for bottles, vials, and other packaging options.
Glass vials used in the pharmaceutical industry are also rising due to the growing demand for injectables. Oncology and other high-potency medications (such antibody conjugates and fast-acting steroids) are in high demand and rising per capita spending on pharmaceuticals is anticipated to be one of the prior growth factors in this market.
Currently, a lot of CDMOs offer services such as drug research, preclinical and clinical trials, manufacturing API and finished products, dosage form development, etc. From medication discovery to commercialization, these services cover the entire value chain. During the projection period, it is projected that the increased complexity of medicines and the lack of internal manufacturing capabilities in many small pharmaceutical businesses would drive the expansion of the CDMO services market.
Recent Developments:
- In Oct 2022, Recipharm strengthened its sterile filling capabilities by acquiring Lab+ technology for low-volume blow-fill-seal (BFS) filling at its Kaysersberg, France facility. BFS is an automated manufacturing procedure in which plastic ampoules are continuously blow-formed, filled, and sealed. Recipharm provides sterile BFS contract manufacturing for a variety of pharmaceutical products and applications, such as gels, solutions, suspensions, emulsions, and aseptically packaged single-use vaccines.
- In Jan 2021, SK Capital Partners LP announced that funds it advises have signed a definitive agreement to acquire the Blow-Fill-Seal ("BFS") Sterile Contract Development and Manufacturing Business (the “Business”) from Catalent Pharma Solutions, LLC.
Competitive Landscape:
Some of the blow Fill Seal CDMO market players:
- Curida
- Horizon Pharmaceuticals
- Unither
- Asept Pak
- Rommelag
- SK Capital
- Ritedose
- ALPS
- Woodstock
- Recipharm
- New Vision Pharmaceuticals
- Nanjing Aureole Pharmaceutical Co., Ltd
- Northland
- Leadingpharm
Market Segmentation:
The blow Fill Seal CDMO market is segmented on the basis of type and application. Type segment includes bottles, ampoules, pre-filled syringes, injectable, and others. The products segment includes medical institutions, research institutes, pharmaceutical company, and others.
Based On Application, The Pharmaceutical Company Segment Is Accounted As A Major Contributor In The Blow Fill Seal CDMO Market
The pharmaceutical company category is expected to hold a major share in the global blow fill seal CDMO. The primary drivers of the pharmaceutical company manufacturing segment growth over the forecast period are the rising number of pharmaceutical companies in the pipeline stage and the expanding use of pharmaceuticals in a wide range of therapies. The manufacturing of completed products is further divided into the production of solid dosage forms, injectables, and other goods.
Injectable Segment Witnessed Growth At A Rapid Rate
The injectable segment is projected to develop at a rapid rate in the global blow Fill Seal CDMO market. Injectables segment is expected to expand significantly over the forecast period due to the rising demand for injectables and preference for injectable delivery systems, such as prefilled syringes and auto-injectors, for the administration of biologics and biosimilars.
In the region, the North America blow fill seal CDMO market holds significant revenue share.
In 2022, the North American CDMO market had the highest value. The market in North America is distinguished by the region's long-standing CDMO presence. Along with this element, expanding partnerships between pharmaceutical firms and CDMOs providing a wide range of services are to blame for the region's leading market share globally.
Blow Fill Seal CDMO Market Report Scope:
|
Report Attribute |
Specifications |
|
Growth rate CAGR |
CAGR of 4.81 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Type And Application |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Curida, Horizon Pharmaceuticals, Unither, Asept Pak, Rommelag, SK Capital, Ritedose, ALPS, Woodstock, Recipharm, New Vision Pharmaceuticals, Nanjing Aureole Pharmaceutical Co., Ltd, Northland, Leadingpharm |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
